The Convergence of Regulatory and Politics: How the President and Congress Will Affect FDA Regulation

Regulatory professionals tend to focus on regulatory requirements, but the political process frequently has significant impacts on how medical products are regulated. Following the 2024 Presidential and Congressional elections, there are major new reform efforts, legislation and executive orders that are having – or will soon likely have – major implications for FDA, the life sciences industry, and even the regulatory profession.

This lively, fast-paced session will feature an objective, non-partisan analysis of the legislation, regulatory reform efforts, executive orders, major court decisions, federal budgets and other changes that regulatory professionals working in the life sciences need to know. We know regulatory professionals want to understand the impacts – not our personal politics.

This presentation will provide participants with specific, actionable information that will help them identify important changes in the political environment and how that will present risks and opportunities in the regulatory environment for pharmaceutical, biologics, medical device, diagnostics and dietary supplement companies. While we’ll be talking about the political process, everything we say will be grounded in regulatory impacts.

Speakers will include a trio of nationally recognized experts in regulatory policy, legislation and the political process who regularly provide briefings to industry, regulators and Congressional staff.